Catalina Lopez Manzano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Catalina Lopez Manzano has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Penny Whiting
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
8 shared publications - Bethany Van Guelpen
Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden
5 shared publications - Chris Cooper
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
5 shared publications - Cornelia M. Ulrich
Huntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, Utah
5 shared publications - David Timothy Bishop
Leeds Institute of Medical Research, University of Leeds, Leeds, UK
5 shared publications - Demetrius Albanes
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, USA
5 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- p. 1-290
Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model
Background: Multiple sclerosis is an immune-mediated inflammatory disease, causing long-term disability in young adults. Most cases begin as relapsing–remitting multiple sclerosis. Some people have a form of relapsing–remitting multiple sclerosis known as highly active relapsing–remitting multiple sclerosis, defined as multiple sclerosis with unchanged or increased disease activity despite prior treatment with at least one disease-modifying therapy. Objectives: To appraise the clinical and cost-effectiveness of natalizumab [Tysabri ® (Biogen, Cambridge, MA, USA)] and natalizumab biosimilar [Tyruko ® (Sandoz)] for treating highly active relapsing–remitting multiple sclerosis compared to other disease-modifying therapy. Design: Systematic review with network meta-analysis and economic model. Searches last updated in April 2024. Results: We included 42 studies (22,409 participants): 40 in people with relapsing–remitting multiple sclerosis and 2 in highly active relapsing–remitting multiple sclerosis. Six studies also reported data separately for highly active relapsing–remitting multiple sclerosis. Only four studies evaluated natalizumab or natalizumab biosimilar; none provided data on those with highly active relapsing–remitting multiple sclerosis. Follow-up ranged from 4 to 36 (median 24) months. Most interventions reduced relapses (39 studies, 17 interventions) and magnetic resonance imaging lesions (19 studies, 11 interventions for gadolinium enhancing lesions and 17 studies, 12 interventions for T2-weighted lesions) compared to placebo. Alemtuzumab, ocrelizumab, cladribine, natalizumab, fingolimod and peginterferon beta-1a reduced disease progression compared to placebo (15 studies, 12 interventions). There were no differences in any adverse events (24 studies, 16 interventions), serious adverse events (31 studies, 15 interventions) or treatment-related adverse events (8 studies, no network meta-analysis) for any intervention compared to placebo. Fingolimod, glatiramer acetate, interferon beta-1a, interferon beta-1b and peginterferon beta-1a were associated with an increased treatment discontinuation (29 studies, 13 interventions). There was little evidence for a difference in quality of life. There was no evidence of a difference between natalizumab and natalizumab biosimilar for relapse rates [rate ratio 0.65 (95% credible interval 0.33 to 1.23], gadolinium enhancing lesions [hazard ratio 1.29 (0.69 to 2.37)], T2-weighted lesions [hazard ratio 1.07 (0.73 to 1.57)], any adverse events [hazard ratio 1.06 (0.77 to 1.46)] or treatment discontinuation [hazard ratio 0.48 (0.13 to 1.76)]. Data in highly active relapsing–remitting multiple sclerosis were available for fingolimod, ocrelizumab, alemtuzumab, cladribine, interferon beta, autologous haematopoietic stem cell treatment and placebo. We also included one study on natalizumab conducted in a population that was close to our definition of highly active relapsing–remitting multiple sclerosis. All interventions except interferon beta-1a were associated with reduced relapse risk compared to placebo (six studies; seven interventions). Compared with natalizumab-intravenous, natalizumab biosimilar-intravenous and natalizumab subcutaneous, all treatments had greater net benefit at £20,000–30,000/quality-adjusted life-year, with the only exception being ocrelizumab, which had lower net benefits. Costs were generally higher on natalizumab than other treatments, though there was no difference in quality-adjusted life-years with 95% credible interval completely overlapping. The results and conclusions were unchanged under all sensitivities. VOI analysis found that the greatest contributor to decision uncertainty was the effectiveness of treatments. Conclusions: There is no direct evidence on the effectiveness of natalizumab or its biosimilar in patients with highly active relapsing–remitting multiple sclerosis. Limited data suggest similar effectiveness in patients with relapsing–remitting multiple sclerosis. The economic model found that natalizumab and natalizumab biosimilar were not cost-effective compared to any of the included comparators in highly active relapsing–remitting multiple sclerosis, with similar quality-adjusted life-years but higher costs, with the only exception being ocrelizumab. Future work: There is need for studies of natalizumab and natalizumab biosimilar in people with highly active relapsing–remitting multiple sclerosis. Study registration: The study is registered as PROSPERO CRD42024556838. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR165943) and is published in full in Health Technology Assessment ; Vol. 30, No. 60. See the NIHR Funding and Awards website for further award information.
- 1 August 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- p. 1-290
Open AccessNatalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model
Background: Multiple sclerosis is an immune-mediated inflammatory disease, causing long-term disability in young adults. Most cases begin as relapsing–remitting multiple sclerosis. Some people have a form of relapsing–remitting multiple sclerosis known as highly active relapsing–remitting multiple sclerosis, defined as multiple sclerosis with unchanged or increased disease activity despite prior treatment with at least one disease-modifying therapy. Objectives: To appraise the clinical and cost-effectiveness of natalizumab [Tysabri ® (Biogen, Cambridge, MA, USA)] and natalizumab biosimilar [Tyruko ® (Sandoz)] for treating highly active relapsing–remitting multiple sclerosis compared to other disease-modifying therapy. Design: Systematic review with network meta-analysis and economic model. Searches last updated in April 2024. Results: We included 42 studies (22,409 participants): 40 in people with relapsing–remitting multiple sclerosis and 2 in highly active relapsing–remitting multiple sclerosis. Six studies also reported data separately for highly active relapsing–remitting multiple sclerosis. Only four studies evaluated natalizumab or natalizumab biosimilar; none provided data on those with highly active relapsing–remitting multiple sclerosis. Follow-up ranged from 4 to 36 (median 24) months. Most interventions reduced relapses (39 studies, 17 interventions) and magnetic resonance imaging lesions (19 studies, 11 interventions for gadolinium enhancing lesions and 17 studies, 12 interventions for T2-weighted lesions) compared to placebo. Alemtuzumab, ocrelizumab, cladribine, natalizumab, fingolimod and peginterferon beta-1a reduced disease progression compared to placebo (15 studies, 12 interventions). There were no differences in any adverse events (24 studies, 16 interventions), serious adverse events (31 studies, 15 interventions) or treatment-related adverse events (8 studies, no network meta-analysis) for any intervention compared to placebo. Fingolimod, glatiramer acetate, interferon beta-1a, interferon beta-1b and peginterferon beta-1a were associated with an increased treatment discontinuation (29 studies, 13 interventions). There was little evidence for a difference in quality of life. There was no evidence of a difference between natalizumab and natalizumab biosimilar for relapse rates [rate ratio 0.65 (95% credible interval 0.33 to 1.23], gadolinium enhancing lesions [hazard ratio 1.29 (0.69 to 2.37)], T2-weighted lesions [hazard ratio 1.07 (0.73 to 1.57)], any adverse events [hazard ratio 1.06 (0.77 to 1.46)] or treatment discontinuation [hazard ratio 0.48 (0.13 to 1.76)]. Data in highly active relapsing–remitting multiple sclerosis were available for fingolimod, ocrelizumab, alemtuzumab, cladribine, interferon beta, autologous haematopoietic stem cell treatment and placebo. We also included one study on natalizumab conducted in a population that was close to our definition of highly active relapsing–remitting multiple sclerosis. All interventions except interferon beta-1a were associated with reduced relapse risk compared to placebo (six studies; seven interventions). Compared with natalizumab-intravenous, natalizumab biosimilar-intravenous and natalizumab subcutaneous, all treatments had greater net benefit at £20,000–30,000/quality-adjusted life-year, with the only exception being ocrelizumab, which had lower net benefits. Costs were generally higher on natalizumab than other treatments, though there was no difference in quality-adjusted life-years with 95% credible interval completely overlapping. The results and conclusions were unchanged under all sensitivities. VOI analysis found that the greatest contributor to decision uncertainty was the effectiveness of treatments. Conclusions: There is no direct evidence on the effectiveness of natalizumab or its biosimilar in patients with highly active relapsing–remitting multiple sclerosis. Limited data suggest similar effectiveness in patients with relapsing–remitting multiple sclerosis. The economic model found that natalizumab and natalizumab biosimilar were not cost-effective compared to any of the included comparators in highly active relapsing–remitting multiple sclerosis, with similar quality-adjusted life-years but higher costs, with the only exception being ocrelizumab. Future work: There is need for studies of natalizumab and natalizumab biosimilar in people with highly active relapsing–remitting multiple sclerosis. Study registration: The study is registered as PROSPERO CRD42024556838. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR165943) and is published in full in Health Technology Assessment ; Vol. 30, No. 60. See the NIHR Funding and Awards website for further award information.
- Open Access
- 10 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70663
Defining Activity‐Based Subgroups in Multiple Sclerosis: A Review and Framework Proposal
Background: Multiple sclerosis (MS) is commonly stratified into activity‐based subgroups to inform treatment decisions and health technology assessments (HTAs). However, the terminology and criteria used to define these subgroups, particularly ‘active’, ‘highly active’ and ‘rapidly evolving severe’ (RES) disease, are inconsistent across clinical trials and regulatory guidance, leading to ambiguity in practice and restricted treatment access. Our objectives were to review how activity‐based subgroups in MS are defined across NICE technology appraisals (TAs) and the randomised controlled trials (RCTs) that inform them, and to propose a preliminary framework for standardised terminology. Methods: We identified and reviewed NICE TAs of disease‐modifying therapies (DMTs) for MS and the RCTs included in those appraisals. We extracted and compared definitions used to characterise activity‐based MS subgroups, and classified them by key components such as relapse history, MRI findings and treatment status. We summarised our findings and highlighted points of consensus and controversy. Results: Definitions varied widely, especially for ‘highly active’ RRMS and active SPMS. While most TAs used consistent criteria for ‘active’ and ‘RES’ RRMS disease, definitions in RCTs were heterogeneous. We identified frequent overlaps in terminology and proposed a simplified framework comprising three distinct but overlapping subgroups for RMS: active RRMS/RRMS, highly active RRMS (HARRMS) and rapidly evolving severe RRMS (RES‐RRMS). Conclusions: Standardised definitions are urgently needed to improve evidence synthesis, inform regulatory guidance and ensure equitable treatment access. We propose a formal consensus process to consolidate this framework for use in future research, HTAs and treatment pathways.
- 10 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70663
Open AccessDefining Activity‐Based Subgroups in Multiple Sclerosis: A Review and Framework Proposal
Background: Multiple sclerosis (MS) is commonly stratified into activity‐based subgroups to inform treatment decisions and health technology assessments (HTAs). However, the terminology and criteria used to define these subgroups, particularly ‘active’, ‘highly active’ and ‘rapidly evolving severe’ (RES) disease, are inconsistent across clinical trials and regulatory guidance, leading to ambiguity in practice and restricted treatment access. Our objectives were to review how activity‐based subgroups in MS are defined across NICE technology appraisals (TAs) and the randomised controlled trials (RCTs) that inform them, and to propose a preliminary framework for standardised terminology. Methods: We identified and reviewed NICE TAs of disease‐modifying therapies (DMTs) for MS and the RCTs included in those appraisals. We extracted and compared definitions used to characterise activity‐based MS subgroups, and classified them by key components such as relapse history, MRI findings and treatment status. We summarised our findings and highlighted points of consensus and controversy. Results: Definitions varied widely, especially for ‘highly active’ RRMS and active SPMS. While most TAs used consistent criteria for ‘active’ and ‘RES’ RRMS disease, definitions in RCTs were heterogeneous. We identified frequent overlaps in terminology and proposed a simplified framework comprising three distinct but overlapping subgroups for RMS: active RRMS/RRMS, highly active RRMS (HARRMS) and rapidly evolving severe RRMS (RES‐RRMS). Conclusions: Standardised definitions are urgently needed to improve evidence synthesis, inform regulatory guidance and ensure equitable treatment access. We propose a formal consensus process to consolidate this framework for use in future research, HTAs and treatment pathways.
- Open Access
- 1 June 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 30 (46) , 1-319
Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model
Background: National Institute for Health and Care Excellence technology appraisals assess the effectiveness and cost-effectiveness of medicines at a single point in the treatment pathway. However, for some disease areas, such as non-small cell lung cancer, there are many recommendations, making it difficult to use National Institute for Health and Care Excellence guidance. The treatment pathway for metastatic stage 4 non-small cell lung cancer can be divided into decision points (nodes) based on histology (squamous or non-squamous), programmed death-ligand 1 expression, presence of tumour mutations and line of therapy. The National Institute for Health and Care Excellence commissioned this pilot to assess the potential of taking a ‘pathways approach’ to technology appraisals. The aim was to build a single disease-specific cost-effectiveness model for metastatic stage 4 non-small cell lung cancer patients not eligible for targeted therapies at first line, that can be updated with economic and clinical data as required. Methods: We conducted a systematic review (searches last updated 11 July 2025) and network meta-analysis of treatment efficacy and safety at each decision node in the pathway. We used flexible fractional polynomial models for primary outcome progression-free survival, required for a model of treatment sequences. We built a novel cost-effectiveness model that compared sequences of treatments, and was populated using network meta-analyses for progression-free survival, data on overall survival after last-line therapy, evidence on treatment sequences from an analysis of systemic anticancer therapy data, and quality of life, cost and resource use estimates from previous technology appraisals. Drug list prices were used, but confidential discounts are available. Results: We included 15 randomised controlled trials and 1 single-arm study in the review, judged as some concerns or low risk of bias. Immunotherapies, in combination with doublet platinum chemotherapy, were most effective first-line treatments, although with higher adverse event rates. Immunotherapy monotherapies were most effective at second line, unless patients were suitable for targeted therapies. Sequences for non-squamous non-small cell lung cancer, programmed death-ligand 1 < 50%: Sequences starting with atezolizumab + bevacizumab + doublet platinum chemotherapy had similar costs and quality-adjusted life-years to sequences starting with pembrolizumab + doublet platinum chemotherapy. Sequences starting with pemetrexed + platinum chemotherapy had the lowest costs but also the lowest total quality-adjusted life-years. Sequences for non-squamous non-small cell lung cancer, programmed death-ligand 1 ≥ 50%: Sequences starting with pembrolizumab + doublet platinum chemotherapy had highest quality-adjusted life-years, but higher costs compared to other sequences. Sequences starting with pemetrexed + platinum chemotherapy had the lowest cost and the lowest number of quality-adjusted life-years. Sequences for squamous non-small cell lung cancer, programmed death-ligand 1 < 50%: Sequences starting with pembrolizumab + doublet platinum chemotherapy had higher quality-adjusted life-years and higher costs than sequences starting with platinum chemotherapy. Sequences for squamous non-small cell lung cancer, programmed death-ligand 1 ≥ 50%: Sequences starting with atezolizumab had the highest predicted quality-adjusted life-year gains, slightly higher than for sequences starting with pembrolizumab. Sequences starting with platinum chemotherapy had the lowest quality-adjusted life-years, but the lowest total costs. Patients in the systemic anticancer therapy analysis had a shorter time on treatment than those in trials, resulting in lower treatment costs and causing the immunotherapy sequences to appear more cost effective. Conclusions: Our model can be used to estimate either the most cost-effective sequence of treatments or the most cost-effective treatment at a given point in the pathway, although our results are based on drug list prices and these would need to be updated to draw conclusions about the relative cost-effectiveness of different treatment sequences. We were able to use real-world data from systemic anticancer therapy to estimate model parameters and sequences that reflect clinical practice. Our model can readily be updated and used as a reference model for metastatic non-small cell lung cancer. Study registration: The study is registered as PROSPERO CRD42023470119. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR136097) and is published in full in Health Technology Assessment ; Vol. 30, No. 46. See the NIHR Funding and Awards website for further award information.
- 1 June 2026
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 30 (46) , 1-319
Open AccessTreatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model
Background: National Institute for Health and Care Excellence technology appraisals assess the effectiveness and cost-effectiveness of medicines at a single point in the treatment pathway. However, for some disease areas, such as non-small cell lung cancer, there are many recommendations, making it difficult to use National Institute for Health and Care Excellence guidance. The treatment pathway for metastatic stage 4 non-small cell lung cancer can be divided into decision points (nodes) based on histology (squamous or non-squamous), programmed death-ligand 1 expression, presence of tumour mutations and line of therapy. The National Institute for Health and Care Excellence commissioned this pilot to assess the potential of taking a ‘pathways approach’ to technology appraisals. The aim was to build a single disease-specific cost-effectiveness model for metastatic stage 4 non-small cell lung cancer patients not eligible for targeted therapies at first line, that can be updated with economic and clinical data as required. Methods: We conducted a systematic review (searches last updated 11 July 2025) and network meta-analysis of treatment efficacy and safety at each decision node in the pathway. We used flexible fractional polynomial models for primary outcome progression-free survival, required for a model of treatment sequences. We built a novel cost-effectiveness model that compared sequences of treatments, and was populated using network meta-analyses for progression-free survival, data on overall survival after last-line therapy, evidence on treatment sequences from an analysis of systemic anticancer therapy data, and quality of life, cost and resource use estimates from previous technology appraisals. Drug list prices were used, but confidential discounts are available. Results: We included 15 randomised controlled trials and 1 single-arm study in the review, judged as some concerns or low risk of bias. Immunotherapies, in combination with doublet platinum chemotherapy, were most effective first-line treatments, although with higher adverse event rates. Immunotherapy monotherapies were most effective at second line, unless patients were suitable for targeted therapies. Sequences for non-squamous non-small cell lung cancer, programmed death-ligand 1 < 50%: Sequences starting with atezolizumab + bevacizumab + doublet platinum chemotherapy had similar costs and quality-adjusted life-years to sequences starting with pembrolizumab + doublet platinum chemotherapy. Sequences starting with pemetrexed + platinum chemotherapy had the lowest costs but also the lowest total quality-adjusted life-years. Sequences for non-squamous non-small cell lung cancer, programmed death-ligand 1 ≥ 50%: Sequences starting with pembrolizumab + doublet platinum chemotherapy had highest quality-adjusted life-years, but higher costs compared to other sequences. Sequences starting with pemetrexed + platinum chemotherapy had the lowest cost and the lowest number of quality-adjusted life-years. Sequences for squamous non-small cell lung cancer, programmed death-ligand 1 < 50%: Sequences starting with pembrolizumab + doublet platinum chemotherapy had higher quality-adjusted life-years and higher costs than sequences starting with platinum chemotherapy. Sequences for squamous non-small cell lung cancer, programmed death-ligand 1 ≥ 50%: Sequences starting with atezolizumab had the highest predicted quality-adjusted life-year gains, slightly higher than for sequences starting with pembrolizumab. Sequences starting with platinum chemotherapy had the lowest quality-adjusted life-years, but the lowest total costs. Patients in the systemic anticancer therapy analysis had a shorter time on treatment than those in trials, resulting in lower treatment costs and causing the immunotherapy sequences to appear more cost effective. Conclusions: Our model can be used to estimate either the most cost-effective sequence of treatments or the most cost-effective treatment at a given point in the pathway, although our results are based on drug list prices and these would need to be updated to draw conclusions about the relative cost-effectiveness of different treatment sequences. We were able to use real-world data from systemic anticancer therapy to estimate model parameters and sequences that reflect clinical practice. Our model can readily be updated and used as a reference model for metastatic non-small cell lung cancer. Study registration: The study is registered as PROSPERO CRD42023470119. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR136097) and is published in full in Health Technology Assessment ; Vol. 30, No. 46. See the NIHR Funding and Awards website for further award information.
- Open Access
- 1 November 2025
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 29 (58) , 1-216
Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
Background: Attention deficit hyperactivity disorder is characterised by inattention, impulsivity and hyperactivity. Diagnosis is complex and time-consuming. Medication requires careful selection and dose titration. Technologies for objective measures of attention deficit hyperactivity disorder that use motion sensors to measure hyperactivity (‘sensor continuous performance tests’) may help improve the diagnostic process and medication management when used in addition to clinical assessment. Objective: To determine whether sensor continuous performance tests are clinically effective and cost-effective to the National Health Service. Specific objectives were to determine the effectiveness of sensor continuous performance tests for: diagnosis of attention deficit hyperactivity disorder in people referred with suspected attention deficit hyperactivity disorder diagnosis of attention deficit hyperactivity disorder in people referred with suspected attention deficit hyperactivity disorder for whom current assessment cannot reach a diagnosis during initial dose titration and treatment decisions for people with attention deficit hyperactivity disorder evaluating treatment effectiveness during long-term treatment monitoring for people with attention deficit hyperactivity disorder. Design: Systematic review and economic model (searches completed 17 November 2023). Results: Objective 1 [29 studies – 25 QbTest (QbTech Ltd., Stockholm, Sweden), 2 EF Sim (Peili Vision, Oulu, Finland) and 2 Nesplora Kids (Giunti Psychometrics, Florence, Italy)]: most evidence was in children. The AQUA trial was the only study to evaluate the QbTest in combination with clinical assessment and included a comparison with clinical assessment alone. Accuracy was similar and there was no statistical evidence of a difference between groups ( p = 0.14), but the study was at high risk of bias. The AQUA trial reported that adding QbTest to the diagnostic process resulted in fewer appointments to reach a diagnosis, reduced consultation time, greater clinician confidence and exclusion of the diagnosis in a more children. Findings were supported by limited data from uncontrolled before–after studies. Qualitative and survey data reported increased clinician confidence in clinical decision-making, reduced time to diagnostic decision and improved communication. Barriers to implementation included staffing, training, technology requirements and length and repetitive content of the test. We found that using QbTest in addition to clinical assessment was likely cost-effective due to the reduced time waiting for assessment, reduced appointments until diagnosis and a higher proportion receiving treatment benefits. Objective 3 (six studies): All evaluated QbTest and most had concerns with risk of bias. Qualitative and survey data suggested that healthcare staff and families valued the QbTest for dose titration, checking medication utility and improving medication adherence. Some data suggested that results may not increase patient understanding and some clinicians highlighted logistical challenges. No studies were identified for objectives 2 and 4. Conclusions: Our results suggest that QbTesting as part of the diagnostic workup for attention deficit hyperactivity disorder in children (age < 18 years), when used in combination with clinical assessment, may be cost-effective. This finding was robust to nearly all assumptions made in the model. There are insufficient data on other sensor continuous performance tests in adults or on medication management. Future work: Diagnostic accuracy study evaluating comparing each of the sensor continuous performance tests plus clinical assessment. This should consider accuracy across different patient subgroups. Trial comparing patient outcomes and process measures in adults and children tested with and without sensor continuous performance tests with separate analyses for difficult-to-diagnose patients. Trial evaluating the role of sensor continuous performance tests in medication management, including long-term follow-up. Limitations: Lack of good-quality data on all tests, both for diagnosis and medication management, particularly when evaluated in combination with clinical information. Study registration: This study is registered as PROSPERO CRD42023482963. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR136009) and is published in full in Health Technology Assessment ; Vol. 29, No. 58. See the NIHR Funding and Awards website for further award information.
- 1 November 2025
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 29 (58) , 1-216
Open AccessClinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
Background: Attention deficit hyperactivity disorder is characterised by inattention, impulsivity and hyperactivity. Diagnosis is complex and time-consuming. Medication requires careful selection and dose titration. Technologies for objective measures of attention deficit hyperactivity disorder that use motion sensors to measure hyperactivity (‘sensor continuous performance tests’) may help improve the diagnostic process and medication management when used in addition to clinical assessment. Objective: To determine whether sensor continuous performance tests are clinically effective and cost-effective to the National Health Service. Specific objectives were to determine the effectiveness of sensor continuous performance tests for: diagnosis of attention deficit hyperactivity disorder in people referred with suspected attention deficit hyperactivity disorder diagnosis of attention deficit hyperactivity disorder in people referred with suspected attention deficit hyperactivity disorder for whom current assessment cannot reach a diagnosis during initial dose titration and treatment decisions for people with attention deficit hyperactivity disorder evaluating treatment effectiveness during long-term treatment monitoring for people with attention deficit hyperactivity disorder. Design: Systematic review and economic model (searches completed 17 November 2023). Results: Objective 1 [29 studies – 25 QbTest (QbTech Ltd., Stockholm, Sweden), 2 EF Sim (Peili Vision, Oulu, Finland) and 2 Nesplora Kids (Giunti Psychometrics, Florence, Italy)]: most evidence was in children. The AQUA trial was the only study to evaluate the QbTest in combination with clinical assessment and included a comparison with clinical assessment alone. Accuracy was similar and there was no statistical evidence of a difference between groups ( p = 0.14), but the study was at high risk of bias. The AQUA trial reported that adding QbTest to the diagnostic process resulted in fewer appointments to reach a diagnosis, reduced consultation time, greater clinician confidence and exclusion of the diagnosis in a more children. Findings were supported by limited data from uncontrolled before–after studies. Qualitative and survey data reported increased clinician confidence in clinical decision-making, reduced time to diagnostic decision and improved communication. Barriers to implementation included staffing, training, technology requirements and length and repetitive content of the test. We found that using QbTest in addition to clinical assessment was likely cost-effective due to the reduced time waiting for assessment, reduced appointments until diagnosis and a higher proportion receiving treatment benefits. Objective 3 (six studies): All evaluated QbTest and most had concerns with risk of bias. Qualitative and survey data suggested that healthcare staff and families valued the QbTest for dose titration, checking medication utility and improving medication adherence. Some data suggested that results may not increase patient understanding and some clinicians highlighted logistical challenges. No studies were identified for objectives 2 and 4. Conclusions: Our results suggest that QbTesting as part of the diagnostic workup for attention deficit hyperactivity disorder in children (age < 18 years), when used in combination with clinical assessment, may be cost-effective. This finding was robust to nearly all assumptions made in the model. There are insufficient data on other sensor continuous performance tests in adults or on medication management. Future work: Diagnostic accuracy study evaluating comparing each of the sensor continuous performance tests plus clinical assessment. This should consider accuracy across different patient subgroups. Trial comparing patient outcomes and process measures in adults and children tested with and without sensor continuous performance tests with separate analyses for difficult-to-diagnose patients. Trial evaluating the role of sensor continuous performance tests in medication management, including long-term follow-up. Limitations: Lack of good-quality data on all tests, both for diagnosis and medication management, particularly when evaluated in combination with clinical information. Study registration: This study is registered as PROSPERO CRD42023482963. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR136009) and is published in full in Health Technology Assessment ; Vol. 29, No. 58. See the NIHR Funding and Awards website for further award information.
- Open Access
Evidence-based blood tests for monitoring adults with chronic kidney disease stage 3 in primary care: rapid review, routine data analysis, and consensus study
Main problem: There is substantial UK variation regarding which blood tests people receive for routine monitoring of stage 3 chronic kidney disease (CKD3) in primary care, suggesting that many people are not receiving optimal care. This study aimed to develop evidence-based testing panels for CKD3. Methods: We considered blood tests used commonly or recommended in CKD3 guidelines, identifying the rationale for each test and then applying a series of filtering questions (e.g. ‘can the GP do anything in response to an abnormal result?’) to identify whether tests should be included in the testing panel. Each question was answered by stepwise rapid evidence reviews. A consensus group, consisting of patient representatives and clinicians, voted on whether tests should be included based on the evidence. If tests had insuficient evidence, additional evidence was collected through rapid reviews or routine data analysis and voted on in a second consensus meeting. Results: There was good evidence for, and consensus supporting, routinely testing eGFR, haemoglobin, and HbA1c; and not routinely testing urea, lipids, vitamin B12, ferritin, folate, liver function, potassium, sodium, vitamin D, calcium, thyroid function, clotting, C-reactive protein, erythrocyte sedimentation rate, and B-type natriuretic peptide. Once on stable treatment, patients on statins do not need additional monitoring tests and patients on ACE-1 or ARB only need potassium monitoring. Conclusions: In contrast to current guidelines, our findings suggest that CKD3 patients should only be routinely ofered eGFR, HbA1c and haemoglobin monitoring. Implementing these recommendations could reduce testing variation in CKD3 patients and reduce costs. Lay summary: Patients with chronic kidney disease are often followed up by their GP. At regular monitoring appointments, blood and urine tests are done to determine whether a change in management is needed, such as adjusting medications. However, which tests are needed at these appointments is not standardised and depending on where you live, the tests that you get may difer because of diferences in local practices. Here, we reviewed the evidence for blood tests that are currently used for patients with chronic kidney disease, and we found that for many tests there is little or no evidence that they are beneficial. We only found good evidence for regular testing of eGFR to test renal function, HbA1c to detect diabetes, and haemoglobin to detect anaemia. Avoiding unnecessary tests is important to prevent overdiagnosis, overtreatment, patient anxiety, and to ensure that resources are focused on efective, evidence-based care.
Open AccessEvidence-based blood tests for monitoring adults with chronic kidney disease stage 3 in primary care: rapid review, routine data analysis, and consensus study
Main problem: There is substantial UK variation regarding which blood tests people receive for routine monitoring of stage 3 chronic kidney disease (CKD3) in primary care, suggesting that many people are not receiving optimal care. This study aimed to develop evidence-based testing panels for CKD3. Methods: We considered blood tests used commonly or recommended in CKD3 guidelines, identifying the rationale for each test and then applying a series of filtering questions (e.g. ‘can the GP do anything in response to an abnormal result?’) to identify whether tests should be included in the testing panel. Each question was answered by stepwise rapid evidence reviews. A consensus group, consisting of patient representatives and clinicians, voted on whether tests should be included based on the evidence. If tests had insuficient evidence, additional evidence was collected through rapid reviews or routine data analysis and voted on in a second consensus meeting. Results: There was good evidence for, and consensus supporting, routinely testing eGFR, haemoglobin, and HbA1c; and not routinely testing urea, lipids, vitamin B12, ferritin, folate, liver function, potassium, sodium, vitamin D, calcium, thyroid function, clotting, C-reactive protein, erythrocyte sedimentation rate, and B-type natriuretic peptide. Once on stable treatment, patients on statins do not need additional monitoring tests and patients on ACE-1 or ARB only need potassium monitoring. Conclusions: In contrast to current guidelines, our findings suggest that CKD3 patients should only be routinely ofered eGFR, HbA1c and haemoglobin monitoring. Implementing these recommendations could reduce testing variation in CKD3 patients and reduce costs. Lay summary: Patients with chronic kidney disease are often followed up by their GP. At regular monitoring appointments, blood and urine tests are done to determine whether a change in management is needed, such as adjusting medications. However, which tests are needed at these appointments is not standardised and depending on where you live, the tests that you get may difer because of diferences in local practices. Here, we reviewed the evidence for blood tests that are currently used for patients with chronic kidney disease, and we found that for many tests there is little or no evidence that they are beneficial. We only found good evidence for regular testing of eGFR to test renal function, HbA1c to detect diabetes, and haemoglobin to detect anaemia. Avoiding unnecessary tests is important to prevent overdiagnosis, overtreatment, patient anxiety, and to ensure that resources are focused on efective, evidence-based care.
- Open Access
Evidence-based blood tests for monitoring adults with hypertension in primary care: rapid review, routine data analyses, and consensus study
Background: Substantial variation in testing rates in adults with hypertension across UK primary care suggest that patients are not receiving optimal monitoring. Aim: To develop a minimal set of evidence-based blood tests for adults with hypertension. Design: Rapid review, routine data analyses, and consensus study. Setting: Primary care. Method: We developed an initial list of tests which were recommended by guidelines or used commonly. We created filtering questions to examine the rationale of each test. To answer each question, we performed stepwise rapid reviews of evidence cited by guidelines, high-quality studies, systematic reviews, and individual studies. A consensus group, including clinicians and patients, voted to include or exclude each test in the testing panel based on the evidence. If there was no consensus (>80%), additional evidence was sought through rapid reviews or analyses of primary care records, which was subject to further voting. Results: We identified 16 tests that are routinely ordered for people with hypertension. We found consistent and good evidence that eGFR to detect chronic kidney disease and HbA1c to detect diabetes is beneficial for patients. We found no or inconsistent evidence of the benefit of routinely measuring lipids, electrolytes, haemoglobin, thyroid function tests, clotting tests, calcium, ferritin, folate acid, or vitamin B12. We found good evidence that there is no benefit in routinely monitoring liver function, inflammation markers, or brain natriuretic peptide. Conclusion: We identified a minimal set of evidence-based tests that should be offered to adults with hypertension. Implementing these recommendations could reduce harms associated with unwarranted variation in care. Further research is needed to clarify the role of tests with inconsistent evidence and determine the optimal frequency of testing. Key messages: What is already known on this topic: There is substantial variation in the use of blood tests to monitor people with hypertension suggesting that many patients are not receiving optimal care. Over-testing can cause patient harm, including patient anxiety, unnecessary downstream tests, referrals, and overdiagnosis, as well as wasting limited NHS resources. What this study adds: We have developed a minimal testing panel for patients with hypertension based on the best available evidence and a consensus process. The panel includes eGFR to screen for chronic kidney disease, HbA1c to screen for diabetes mellitus, potassium for patients on ACE inhibiters and angiotensin II receptor blockers. How this study might affect research, practice or policy – summarise the implications of this study: Unnecessary testing could be prevented if guidelines and local protocols recommended minimal testing sets and made clear additional tests should only be added if clinically indicated. Future research needs to address optimal testing intervals and test thresholds.
Open AccessEvidence-based blood tests for monitoring adults with hypertension in primary care: rapid review, routine data analyses, and consensus study
Background: Substantial variation in testing rates in adults with hypertension across UK primary care suggest that patients are not receiving optimal monitoring. Aim: To develop a minimal set of evidence-based blood tests for adults with hypertension. Design: Rapid review, routine data analyses, and consensus study. Setting: Primary care. Method: We developed an initial list of tests which were recommended by guidelines or used commonly. We created filtering questions to examine the rationale of each test. To answer each question, we performed stepwise rapid reviews of evidence cited by guidelines, high-quality studies, systematic reviews, and individual studies. A consensus group, including clinicians and patients, voted to include or exclude each test in the testing panel based on the evidence. If there was no consensus (>80%), additional evidence was sought through rapid reviews or analyses of primary care records, which was subject to further voting. Results: We identified 16 tests that are routinely ordered for people with hypertension. We found consistent and good evidence that eGFR to detect chronic kidney disease and HbA1c to detect diabetes is beneficial for patients. We found no or inconsistent evidence of the benefit of routinely measuring lipids, electrolytes, haemoglobin, thyroid function tests, clotting tests, calcium, ferritin, folate acid, or vitamin B12. We found good evidence that there is no benefit in routinely monitoring liver function, inflammation markers, or brain natriuretic peptide. Conclusion: We identified a minimal set of evidence-based tests that should be offered to adults with hypertension. Implementing these recommendations could reduce harms associated with unwarranted variation in care. Further research is needed to clarify the role of tests with inconsistent evidence and determine the optimal frequency of testing. Key messages: What is already known on this topic: There is substantial variation in the use of blood tests to monitor people with hypertension suggesting that many patients are not receiving optimal care. Over-testing can cause patient harm, including patient anxiety, unnecessary downstream tests, referrals, and overdiagnosis, as well as wasting limited NHS resources. What this study adds: We have developed a minimal testing panel for patients with hypertension based on the best available evidence and a consensus process. The panel includes eGFR to screen for chronic kidney disease, HbA1c to screen for diabetes mellitus, potassium for patients on ACE inhibiters and angiotensin II receptor blockers. How this study might affect research, practice or policy – summarise the implications of this study: Unnecessary testing could be prevented if guidelines and local protocols recommended minimal testing sets and made clear additional tests should only be added if clinically indicated. Future research needs to address optimal testing intervals and test thresholds.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis
Power calculations for genetically predicted ghrelin and colorectal cancer risk
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis
Power calculations for genetically predicted ghrelin and colorectal cancer risk
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis
Background:Epidemiological and laboratory-based studies have provided conflicting evidence for a role of ghrelin in colorectal cancer development. We conducted two-sample Mendelian randomization (MR) analyses to evaluate evidence for an association of circulating ghrelin and colorectal cancer risk overall and by sex, cancer subsite, and age at diagnosis.Methods:Genetic instruments proxying plasma total ghrelin levels were obtained from a recent genome-wide association study of 54,219 participants. Summary data for colorectal cancer risk were obtained from a recent meta-analysis of several genetic consortia (up to 73,673 cases and 86,854 controls). A two-sample MR approach and several sensitivity analyses were applied.Results:We found no evidence for an association of genetically predicted plasma total ghrelin levels and colorectal cancer risk (0.95, 95% confidence interval, 0.81–1.12; R2 of ghrelin genetic instruments: 4.6%), with similarly null results observed when stratified by sex, anatomical subsite, and for early-onset colorectal cancer.Conclusions:Our study suggests that plasma ghrelin levels are unlikely to have a causal relationship with overall, early-onset, and sex- and cancer subsite–stratified colorectal cancer risk.Impact:This large-scale analysis adds to the growing body of evidence that plasma total ghrelin levels are not associated with colorectal cancer risk.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis
Background:Epidemiological and laboratory-based studies have provided conflicting evidence for a role of ghrelin in colorectal cancer development. We conducted two-sample Mendelian randomization (MR) analyses to evaluate evidence for an association of circulating ghrelin and colorectal cancer risk overall and by sex, cancer subsite, and age at diagnosis.Methods:Genetic instruments proxying plasma total ghrelin levels were obtained from a recent genome-wide association study of 54,219 participants. Summary data for colorectal cancer risk were obtained from a recent meta-analysis of several genetic consortia (up to 73,673 cases and 86,854 controls). A two-sample MR approach and several sensitivity analyses were applied.Results:We found no evidence for an association of genetically predicted plasma total ghrelin levels and colorectal cancer risk (0.95, 95% confidence interval, 0.81–1.12; R2 of ghrelin genetic instruments: 4.6%), with similarly null results observed when stratified by sex, anatomical subsite, and for early-onset colorectal cancer.Conclusions:Our study suggests that plasma ghrelin levels are unlikely to have a causal relationship with overall, early-onset, and sex- and cancer subsite–stratified colorectal cancer risk.Impact:This large-scale analysis adds to the growing body of evidence that plasma total ghrelin levels are not associated with colorectal cancer risk.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis
Cancer betas for the SNPs associated with plasma ghrelin
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis
Cancer betas for the SNPs associated with plasma ghrelin
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis
SNPs associated with plasma ghrelin
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis
SNPs associated with plasma ghrelin